MD Peers & Perspectives

The Economics of Newer Versus Older Drugs in Treating MRSA

Published Online: Thursday, October 6, 2011
When treating methicillin-resistant Staphylococcus aureus infection, some clinicians have argued that newer, costlier drugs can save money if used from the beginning in place of older, cheaper alternatives. (This is an audio outtake from an expert discussion on MRSA prevention, recognition, and treatment. To read our article based on the discussion, click here.)

Comment(s)
Your comments are valuable to us. Thank you.
*Required
*Name
*Email Address
Body

 




Become a Member